Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.70 |
| ▸ | CA12 | O43570 | 16/20 | 0.70 |
| ▸ | CA1 | P00915 | 16/20 | 0.70 |
| ▸ | CA9 | Q16790 | 16/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3412568 | 0.84 | PTPN7 (0.70) | CA2CA12CA1CA9KMT2A | |
| SCHEMBL671546 | 0.82 | CA2 (1.00) | CA2CA12CA1CA9CYP1A2 | |
| SCHEMBL672763 | 0.82 | CA12 (1.00) | CA2CA12CA1CA9CYP1A2 | |
| SCHEMBL28499329 | 0.82 | KMT2A (1.00) | CA2CA12CA1CA9KMT2A | |
| SCHEMBL673381 | 0.81 | CA12 (1.00) | CA2CA12CA1CA9KMT2A | |
| SCHEMBL5452136 | 0.81 | SMN1; SMN2 (0.65) | KMT2APOLBMEN1 | |
| SCHEMBL30090655 | 0.80 | CA2 (1.00) | CA2CA12CA1CA9CYP1A2 | |
| SCHEMBL1463249 | 0.80 | POLB (1.00) | CA2CA12CA1CA9CYP1A2 | |
| SCHEMBL673159 | 0.80 | CA2 (1.00) | CA2CA12CA1CA9CYP1A2 | |
| SCHEMBL672985 | 0.79 | CA2 (1.00) | CA2CA12CA1CA9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2823826-A2 | Inhibitors of carbonic anhydrase IX | Molecular Insight Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2823826-A2 | Inhibitors of carbonic anhydrase IX | Molecular Insight Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8877970-B2 | Inhibitors of carbonic anhydrase IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877970-B2 | Inhibitors of carbonic anhydrase IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2240171-A2 | INHIBITORS OF CARBONIC ANHYDRASE IX | Molecular Insight Pharmaceuticals, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009089383-A2 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009089383-A2 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | CA9, CA12, CA1 | CA2 7/4885CA12 2/4885CA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.